Works matching AU Heerspink, Hiddo J. L.

Results: 176

Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 8, p. 4415, doi. 10.1111/dom.16478

By:

Beernink, Jelle M.;
Jongs, Niels;
Mosterd, Charlotte M.;
Scholtes, Rosalie A.;
Caldwell‐McGee, Alyssa;
Casillas, Daniel;
Driscoll, Lynette;
Greasley, Peter J.;
Karlsson, Cecilia;
Hammarstedt, Ann;
Sridhar, Vikas S.;
Muskiet, Marcel H. A.;
Laverman, Gozewijn D.;
Cherney, David Z. I.;
Bjornstad, Petter;
van Raalte, Daniel H.;
Heerspink, Hiddo J. L.

Publication type:

Article

Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 8, p. 4311, doi. 10.1111/dom.16468

By:

Wasehuus, Victor;
Smeijer, J. David;
Ambery, Phil;
Greasley, Peter J.;
Wijkmark, Emma;
Wheeler, David C.;
Rossing, Peter;
Heerspink, Hiddo J. L.

Publication type:

Article

Indirect Insulin Resistance Indices and Their Cut-Off Values for the Prediction of Post-Transplantation Diabetes Mellitus in Kidney Transplant Recipients.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 23, p. 7296, doi. 10.3390/jcm12237296

By:

Sokooti, Sara;
Szili-Török, Tamás;
Heerspink, Hiddo J. L.;
Dullaart, Robin P. F.;
Bakker, Stephan J. L.

Publication type:

Article

Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors.

Published in:

Journal of Clinical Medicine, 2019, v. 8, n. 6, p. 779, doi. 10.3390/jcm8060779

By:

Eickhoff, Mie K.;
Dekkers, Claire C. J.;
Kramers, Bart J.;
Laverman, Gozewijn Dirk;
Frimodt-Møller, Marie;
Jørgensen, Niklas Rye;
Faber, Jens;
Danser, A. H. Jan;
Gansevoort, Ron T.;
Rossing, Peter;
Persson, Frederik;
Heerspink, Hiddo J. L.

Publication type:

Article

Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care.

Published in:

Journal of Clinical Medicine, 2018, v. 7, n. 12, p. 499, doi. 10.3390/jcm7120499

By:

Provenzano, Michele;
Minutolo, Roberto;
Chiodini, Paolo;
Bellizzi, Vincenzo;
Nappi, Felice;
Russo, Domenico;
Borrelli, Silvio;
Garofalo, Carlo;
Iodice, Carmela;
De Stefano, Toni;
Conte, Giuseppe;
Heerspink, Hiddo J. L.;
De Nicola, Luca

Publication type:

Article

Kinetics of endothelin-1 and effect selective ET<sub>A</sub> antagonism on ET<sub>B</sub> activation: a mathematical modeling analysis.

Published in:

Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1332388

By:

Hallow, K. Melissa;
Greasley, Peter J.;
Heerspink, Hiddo J. L.;
Yu, Hongtao

Publication type:

Article

Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 4, p. 1972, doi. 10.1111/dom.16190

By:

Siriwardana, Amanda;
Buizen, Luke;
Jun, Min;
Kotwal, Sradha;
Arnott, Clare;
Jardine, Meg J.;
Levin, Adeera;
Heerspink, Hiddo J. L.;
Charytan, David M.;
Pollock, Carol;
Perkovic, Vlado;
Neuen, Brendon L.

Publication type:

Article

The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 511, doi. 10.1111/dom.16041

By:

Smeijer, Johannes David;
Gomez, Maria F.;
Rossing, Peter;
Heerspink, Hiddo J. L.

Publication type:

Article

Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3371, doi. 10.1111/dom.15678

By:

Tangri, Navdeep;
Ferguson, Thomas W.;
Bamforth, Ryan J.;
Leon, Silvia J.;
Arnott, Clare;
Mahaffey, Kenneth W.;
Kotwal, Sradha;
Heerspink, Hiddo J. L.;
Perkovic, Vlado;
Fletcher, Robert A.;
Neuen, Brendon L.

Publication type:

Article

Prediction of new‐onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2741, doi. 10.1111/dom.15592

By:

Said, Fatema;
Arnott, Clare;
Voors, Adriaan A.;
Heerspink, Hiddo J. L.;
ter Maaten, Jozine M.

Publication type:

Article

Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2128, doi. 10.1111/dom.15518

By:

Bornstein, Stefan R.;
de Zeeuw, Dick;
Heerspink, Hiddo J. L.;
Schulze, Friedrich;
Cronin, Lisa;
Wenz, Arne;
Tuttle, Katherine R.;
Hadjadj, Samy;
Rossing, Peter

Publication type:

Article

Front Cover.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. C1, doi. 10.1111/dom.15489

By:

Eissing, Thomas;
Goulooze, Sebastiaan Camiel;
van den Berg, Paul;
van Noort, Martijn;
Ruppert, Martijn;
Snelder, Nelleke;
Garmann, Dirk;
Lippert, Joerg;
Heinig, Roland;
Brinker, Meike;
Heerspink, Hiddo J. L.

Publication type:

Article

Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO‐DKD and FIDELIO‐DKD.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 924, doi. 10.1111/dom.15387

By:

Eissing, Thomas;
Goulooze, Sebastiaan Camiel;
van den Berg, Paul;
van Noort, Martijn;
Ruppert, Martijn;
Snelder, Nelleke;
Garmann, Dirk;
Lippert, Joerg;
Heinig, Roland;
Brinker, Meike;
Heerspink, Hiddo J. L.

Publication type:

Article

Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post‐hoc analysis of the ROTATE‐3 study.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 576, doi. 10.1111/dom.15346

By:

Lieverse, Tom T. G. F.;
Puchades, Maria J.;
Mulder, Udo D. J.;
Provenzano, Michele;
Krenning, Guido;
Jongs, Niels;
Wink, Simon E.;
Slart, Riemer H. J. A.;
Andreucci, Michele;
D'Marco, Luis;
De Nicola, Luca;
Gorriz, Jose L.;
Heerspink, Hiddo J. L.

Publication type:

Article

Derivation and independent validation of kidneyintelX.dkd: A prognostic test for the assessment of diabetic kidney disease progression.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3779, doi. 10.1111/dom.15273

By:

Nadkarni, Girish N.;
Stapleton, Sharon;
Takale, Dipti;
Edwards, Katherine;
Moran, Kara;
Mosoyan, Gohar;
Hansen, Michael K.;
Donovan, Michael J.;
Heerspink, Hiddo J. L.;
Fleming, Fergus;
Coca, Steven G.

Publication type:

Article

The effects of canagliflozin in type 2 diabetes in subgroups defined by population‐specific body mass index: Insights from the CANVAS Program and CREDENCE trial.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3724, doi. 10.1111/dom.15267

By:

Yu, Jie;
Sweeting, Arianne N.;
Gianacas, Chris;
Houston, Lauren;
Lee, Vivian;
Fletcher, Robert A.;
Perkovic, Vlado;
Li, Qiang;
Neuen, Brendon L.;
Berwanger, Otavio;
Heerspink, Hiddo J. L.;
de Zeeuw, Dick;
Arnott, Clare

Publication type:

Article

Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 11, p. 3327, doi. 10.1111/dom.15232

By:

Heerspink, Hiddo J. L.;
Vart, Priya;
Jongs, Niels;
Neuen, Brendon L.;
Bakris, George;
Claggett, Brian;
Vaduganathan, Muthiah;
McCausland, Finnian;
Docherty, Kieran F.;
Jhund, Pardeep S.;
Solomon, Scott D.;
Perkovic, Vlado;
McMurray, John J. V.

Publication type:

Article

Overall and inter‐individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 11, p. 3152, doi. 10.1111/dom.15209

By:

Rotbain Curovic, Viktor;
Houlind, Morten B.;
Kroonen, Marjolein Y. A. M.;
Jongs, Niels;
Zobel, Emilie H.;
Hansen, Tine W.;
Tavenier, Juliette;
Eugen‐Olsen, Jesper;
Laverman, Gozewijn D.;
Kooy, Adriaan;
Persson, Frederik;
Rossing, Peter;
Heerspink, Hiddo J. L.

Publication type:

Article

Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open‐label, crossover trial.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3064, doi. 10.1111/dom.15180

By:

Laursen, Jens Christian;
Rotbain Curovic, Viktor;
Kroonen, Marjolein Y. A. M.;
Jongs, Niels;
Zobel, Emilie H.;
Hansen, Tine W.;
Frimodt‐Møller, Marie;
Laverman, Gozewijn D.;
Kooy, Adriaan;
Persson, Frederik;
Heerspink, Hiddo J. L.;
Hansen, Christian Stevns;
Rossing, Peter

Publication type:

Article

Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2419, doi. 10.1111/dom.15110

By:

Smeijer, J. David;
Kohan, Donald E.;
de Zeeuw, Dick;
Heerspink, Hiddo J. L.

Publication type:

Article

Effects of albuminuria‐lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2413, doi. 10.1111/dom.15109

By:

Sen, Taha;
Curovic, Viktor Rotbain;
Jongs, Niels;
Laverman, Gozewijn D.;
Kooy, Adriaan;
Persson, Frederik;
Rossing, Peter;
Heerspink, Hiddo J. L.

Publication type:

Article

Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2410, doi. 10.1111/dom.15103

By:

Kohan, Donald E.;
Liew, Adrian;
Tang, Sydney C. W.;
Barratt, Jonathan;
Heerspink, Hiddo J. L.

Publication type:

Article

Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2218, doi. 10.1111/dom.15099

By:

Cherney, David Z. I.;
de Zeeuw, Dick;
Heerspink, Hiddo J. L.;
Cardona, Jose;
Desch, Marc;
Wenz, Arne;
Schulze, Friedrich;
Nangaku, Masaomi

Publication type:

Article

The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2151, doi. 10.1111/dom.15091

By:

Kang, Amy;
Smyth, Brendan;
Neuen, Brendon L.;
Heerspink, Hiddo J. L.;
Di Tanna, Gian Luca;
Zhang, Hong;
Arnott, Clare;
Hockham, Carinna;
Agarwal, Rajiv;
Bakris, George;
Charytan, David M.;
de Zeeuw, Dick;
Greene, Tom;
Levin, Adeera;
Pollock, Carol;
Wheeler, David C.;
Mahaffey, Kenneth W.;
Perkovic, Vlado;
Jardine, Meg J.

Publication type:

Article

Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1758, doi. 10.1111/dom.15033

By:

van der Aart‐van der Beek, Annemarie B.;
Apperloo, Ellen;
Jongs, Niels;
Rouw, Dennis B.;
Sjöström, C. David;
Friedli, Iris;
Johansson, Lars;
van Raalte, Daniël H.;
Hoogenberg, Klaas;
Heerspink, Hiddo J. L.

Publication type:

Article

The importance of targeting multiple risk markers in patients with type 2 diabetes: A post‐hoc study from the CANVAS programme.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1638, doi. 10.1111/dom.15018

By:

Tye, SokCin;
Oshima, Megumi;
Arnott, Clare;
Neuen, Brendon L.;
Fletcher, Robert A.;
Neal, Bruce;
Heerspink, Hiddo J. L.

Publication type:

Article

Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1413, doi. 10.1111/dom.14978

By:

Koshino, Akihiko;
Oshima, Megumi;
Arnott, Clare;
Fletcher, Robert A.;
Bakris, George L.;
Jardine, Meg;
Mahaffey, Kenneth W.;
Perkovic, Vlado;
Pollock, Carol;
Heerspink, Hiddo J. L.;
Neuen, Brendon L.

Publication type:

Article

Mechanisms underlying the blood pressure‐lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 198, doi. 10.1111/dom.14864

By:

Scholtes, Rosalie A.;
Mosterd, Charlotte M.;
Hesp, Anne C.;
Smits, Mark M.;
Heerspink, Hiddo J. L.;
van Raalte, Daniël H.

Publication type:

Article

Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 10, p. 1950, doi. 10.1111/dom.14779

By:

Sen, Taha;
Koshino, Akihiko;
Neal, Bruce;
Bijlsma, Maarten J.;
Arnott, Clare;
Li, Jingwei;
Hansen, Michael K.;
Ix, Joachim H.;
Heerspink, Hiddo J. L.

Publication type:

Article

Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta‐analysis.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 10, p. 1927, doi. 10.1111/dom.14772

By:

Li, Chao;
Yu, Jie;
Hockham, Carinna;
Perkovic, Vlado;
Neuen, Brendon L.;
Badve, Sunil V.;
Houston, Lauren;
Lee, Vivian Y. J.;
Barraclough, Jennifer Y.;
Fletcher, Robert A.;
Mahaffey, Kenneth W.;
Heerspink, Hiddo J. L.;
Cannon, Christopher P.;
Neal, Bruce;
Arnott, Clare

Publication type:

Article

Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1429, doi. 10.1111/dom.14731

By:

Miyamoto, Satoshi;
Heerspink, Hiddo J. L.;
de Zeeuw, Dick;
Toyoda, Masao;
Suzuki, Daisuke;
Hatanaka, Takashi;
Nakamura, Tohru;
Kamei, Shinji;
Murao, Satoshi;
Hida, Kazuyuki;
Ando, Shinichiro;
Akai, Hiroaki;
Takahashi, Yasushi;
Koya, Daisuke;
Kitada, Munehiro;
Sugano, Hisashi;
Nunoue, Tomokazu;
Nakamura, Akihiko;
Sasaki, Motofumi;
Nakatou, Tatsuaki

Publication type:

Article

Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1578, doi. 10.1111/dom.14729

By:

Sen, Taha;
Scholtes, Rosalie;
Greasley, Peter J.;
Cherney, David Z. I.;
Dekkers, Claire C. J.;
Vervloet, Marc;
Danser, Alexander H. J.;
Barbour, Sean J.;
Karlsson, Cecilia;
Hammarstedt, Ann;
Li, Qiang;
Laverman, Gozewijn D.;
Bjornstad, Petter;
van Raalte, Daniel H.;
Heerspink, Hiddo J. L.

Publication type:

Article

Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1360, doi. 10.1111/dom.14712

By:

Parker, Victoria E. R.;
Hoang, Thuong;
Schlichthaar, Heike;
Gibb, Fraser W.;
Wenzel, Barbara;
Posch, Maximillian G.;
Rose, Ludger;
Chang, Yi‐Ting;
Petrone, Marcella;
Hansen, Lars;
Ambery, Philip;
Jermutus, Lutz;
Heerspink, Hiddo J. L.;
McCrimmon, Rory J.

Publication type:

Article

Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 1072, doi. 10.1111/dom.14671

By:

Barraclough, Jennifer Y.;
Yu, Jie;
Figtree, Gemma A.;
Perkovic, Vlado;
Heerspink, Hiddo J. L.;
Neuen, Brendon L.;
Cannon, Christopher P.;
Mahaffey, Kenneth W.;
Schutte, Aletta E.;
Neal, Bruce;
Arnott, Clare

Publication type:

Article

Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 983, doi. 10.1111/dom.14660

By:

Waijer, Simke W.;
Provenzano, Michele;
Mulder, Skander;
Rossing, Peter;
Persson, Frederik;
Perkovic, Vlado;
Heerspink, Hiddo J. L.

Publication type:

Article

Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 827, doi. 10.1111/dom.14641

By:

Chertow, Glenn M.;
Vart, Priya;
Jongs, Niels;
Langkilde, Anna Maria;
McMurray, John J. V.;
Correa‐Rotter, Ricardo;
Rossing, Peter;
Sjöström, C. David;
Stefansson, Bergur V.;
Toto, Robert D.;
Wheeler, David C.;
Heerspink, Hiddo J. L.

Publication type:

Article

Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 8, p. 1961, doi. 10.1111/dom.14411

By:

van der Aart‐van der Beek, Annemarie B.;
Cherney, David;
Laverman, Gozewijn D.;
Stefansson, Bergur;
Raalte, Daniel H.;
Hoogenberg, Klaas;
Reyner, Daniel;
Li, Qiang;
Di Tanna, Gian Luca;
Greasley, Peter J.;
Heerspink, Hiddo J. L.

Publication type:

Article

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 8, p. 1851, doi. 10.1111/dom.14410

By:

Ruiten, Charlotte C.;
der Aart‐van der Beek, Annemarie B;
IJzerman, Richard G.;
Nieuwdorp, Max;
Hoogenberg, Klaas;
Raalte, Daniël H;
Heerspink, Hiddo J. L.

Publication type:

Article

Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 8, p. 1956, doi. 10.1111/dom.14401

By:

Khunti, Kamlesh;
Charbonnel, Bernard;
Chen, Hungta;
Cherney, David Z.;
Cooper, Andrew;
Fenici, Peter;
Gomes, Marilia B.;
Hammar, Niklas;
Heerspink, Hiddo J. L.;
Ji, Linong;
Medina, Jesús;
Nicolucci, Antonio;
Ramirez, Larisa;
Rathmann, Wolfgang;
Shestakova, Marina V.;
Shimomura, Iichiro;
Tang, Fengming;
Watada, Hirotaka;
Kosiborod, Mikhail

Publication type:

Article

The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 7, p. 1652, doi. 10.1111/dom.14386

By:

Arnott, Clare;
Li, Jing‐Wei;
Cannon, Christopher P.;
Zeeuw, Dick;
Neuen, Brendon L.;
Heerspink, Hiddo J. L.;
Charytan, David M.;
Agarwal, Anubha;
Huffman, Mark D.;
Figtree, Gemma A.;
Bakris, George;
Chang, Tara I‐Hsin;
Feng, Kent;
Rosenthal, Norman;
Zinman, Bernard;
Jardine, Meg J.;
Perkovic, Vlado;
Neal, Bruce;
Mahaffey, Kenneth W.

Publication type:

Article

Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1420, doi. 10.1111/dom.14351

By:

Jun, Min;
Harris, Katie;
Heerspink, Hiddo J. L.;
Badve, Sunil V.;
Jardine, Meg J.;
Harrap, Stephen;
Hamet, Pavel;
Marre, Michel;
Poulter, Neil;
Kotwal, Sradha;
Gallagher, Martin;
Perkovic, Vlado;
Chalmers, John;
Woodward, Mark

Publication type:

Article

Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 561, doi. 10.1111/dom.14252

By:

Koomen, Jeroen V.;
Stevens, Jasper;
Bakris, George;
Correa‐Rotter, Ricardo;
Hou, Fan Fan;
Kitzman, Dalane W.;
Kohan, Donald;
Makino, Hirofumi;
McMurray, John J. V.;
Parving, Hans‐Henrik;
Perkovic, Vlado;
Tobe, Sheldon W.;
Zeeuw, Dick;
Heerspink, Hiddo J. L.

Publication type:

Article

Renal outcomes and all‐cause death associated with sodium‐glucose co‐transporter‐2 inhibitors versus other glucose‐lowering drugs (CVD‐REAL 3 Korea).

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 455, doi. 10.1111/dom.14239

By:

Koh, Eun Sil;
Han, Kyungdo;
Nam, You‐Seon;
Wittbrodt, Eric T.;
Fenici, Peter;
Kosiborod, Mikhail N.;
Heerspink, Hiddo J. L.;
Yoo, Soon‐Jib;
Kwon, Hyuk‐Sang

Publication type:

Article

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 382, doi. 10.1111/dom.14226

By:

Neuen, Brendon L.;
Arnott, Clare;
Perkovic, Vlado;
Figtree, Gemma;
Zeeuw, Dick;
Fulcher, Greg;
Jun, Min;
Jardine, Meg J.;
Zoungas, Sophia;
Pollock, Carol;
Mahaffey, Kenneth W.;
Neal, Bruce;
Heerspink, Hiddo J. L.

Publication type:

Article

Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2493, doi. 10.1111/dom.14175

By:

van der Aart‐van der Beek, Annemarie B.;
Clegg, Lindsay E.;
Penland, Robert C.;
Boulton, David W.;
Sjöström, C. David;
Mentz, Robert J.;
Holman, Rury R.;
Heerspink, Hiddo J. L.

Publication type:

Article

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 2077, doi. 10.1111/dom.14126

By:

Mosenzon, Ofri;
Bain, Stephen C.;
Heerspink, Hiddo J. L.;
Idorn, Thomas;
Mann, Johannes F. E.;
Persson, Frederik;
Pratley, Richard E.;
Rasmussen, Søren;
Rossing, Peter;
von Scholten, Bernt Johan;
Raz, Itamar

Publication type:

Article

Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study).

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1220, doi. 10.1111/dom.14024

By:

Boer, Stefanie A.;
Reijrink, Melanie;
Abdulahad, Wayel H.;
Hoekstra, Elisa S.;
Slart, Riemer H. J. A.;
Heerspink, Hiddo J. L.;
Westra, Johanna;
Mulder, Douwe J.

Publication type:

Article

A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1157, doi. 10.1111/dom.14018

By:

Mulder, Skander;
Hammarstedt, Ann;
Nagaraj, Sunil B.;
Nair, Viji;
Ju, Wenjun;
Hedberg, Jonatan;
Greasley, Peter J.;
Eriksson, Jan W.;
Oscarsson, Jan;
Heerspink, Hiddo J. L.

Publication type:

Article

Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 6, p. 916, doi. 10.1111/dom.13976

By:

Kroonen, Marjolein Y. A. M.;
Koomen, Jeroen V.;
Petrykiv, Sergei I.;
Laverman, Gozewijn D.;
Heerspink, Hiddo J. L.;
Stevens, Jasper

Publication type:

Article

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 5, p. 798, doi. 10.1111/dom.13958

By:

Idzerda, Nienke M. A.;
Clegg, Lindsay E.;
Hernandez, Adrian F.;
Bakris, George;
Penland, Robert C.;
Boulton, David W.;
Bethel, M. Angelyn;
Holman, Rury R.;
Heerspink, Hiddo J. L.

Publication type:

Article